RNAC
Cartesian Therapeutics, Inc.
Price Chart
Latest Quote
$9.63
-0.25 (-2.53%)
Current Price
| Previous Close | $9.88 |
| Open | $10.10 |
| Day High | $10.39 |
| Day Low | $9.48 |
| Volume | 345,307 |
Stock Information
| Shares Outstanding | 29.38M |
| Total Debt | $11.86M |
| Cash Equivalents | $118.64M |
| Revenue | $1.77M |
| Net Income | $-151.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $282.94M |
| EPS (TTM) | $-5.80 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $176.16M |
| Sales | $1.77M |
| Income | $-151.77M |
| Book/sh | $-5.19 |
| Cash/sh | $4.04 |
| Employees | 75 |
Financial Ratios
| Quick Ratio | 7.46 |
| Current Ratio | 7.65 |
Returns & Margins
| ROA | -16.36% |
| Operating Margin | -33973.08% |
Ownership
| Insider Ownership | 53.68% |
| Institutional Ownership | 24.50% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.59 |
| P/S | 159.41 |
| P/B | -1.86 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $34.57 |
Technical Indicators
| SMA20 | $7.42 |
| SMA50 | $7.20 |
| SMA200 | $7.70 |
| RSI | 62.47 |
| ATR | 1.1834 |
| Shares Float | 10.63M |
| Short Float | 17.63% |
| Short Ratio | 12.43 |
| Volatility | 0.78 |
| Rel Volume | 0.78 |
Performance History
| Week | +19.48% |
| Month | +58.13% |
| Quarter | +46.58% |
| 6 Months | +16.16% |
| YTD | +42.46% |
| Year | -1.63% |
| 3 Years | -76.57% |
| 5 Years | -93.54% |
| 10 Years | -97.71% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $9.63 | 354,800 |
| 2026-06-17 | $9.88 | 604,800 |
| 2026-06-16 | $9.05 | 368,100 |
| 2026-06-15 | $8.60 | 259,800 |
| 2026-06-12 | $9.51 | 877,600 |
| 2026-06-11 | $8.06 | 508,000 |
| 2026-06-10 | $7.43 | 545,700 |
| 2026-06-09 | $6.85 | 3,494,800 |
| 2026-06-08 | $5.86 | 143,800 |
| 2026-06-05 | $5.84 | 278,800 |
| 2026-06-04 | $6.55 | 87,500 |
| 2026-06-03 | $6.26 | 172,800 |
| 2026-06-02 | $6.41 | 154,100 |
| 2026-06-01 | $6.92 | 139,300 |
| 2026-05-29 | $7.54 | 238,100 |
| 2026-05-28 | $7.21 | 150,600 |
| 2026-05-27 | $6.93 | 169,700 |
| 2026-05-26 | $6.45 | 370,300 |
| 2026-05-22 | $6.75 | 109,000 |
| 2026-05-21 | $6.68 | 126,300 |
| 2026-05-20 | $6.52 | 178,100 |
| 2026-05-19 | $6.09 | 208,700 |
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
đ° Latest News
AstraZenecaâs âextensiveâ obesity drug push; $125M for ultrasound-aided genetic medicine
BioPharma Dive âĸ 2026-06-10T09:12:00Z
FDA Clears Imvivaâs Dual-Target CAR-T for Autoimmune Diseases
Exec Edge âĸ 2026-06-09T21:19:19Z
We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate
Simply Wall St. âĸ 2026-05-17T14:04:11Z
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-04-30T12:30:12Z
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-04-20T11:59:00Z
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-01-14T17:00:04Z
Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation
Simply Wall St. âĸ 2025-12-05T12:34:42Z
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders have significant skin in the game with 58% ownership
Simply Wall St. âĸ 2025-11-08T12:31:55Z
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Zacks âĸ 2025-10-28T12:45:01Z
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Zacks âĸ 2025-10-21T07:53:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,797,000 | $38,913,000 | $26,004,000 | $110,777,000 |
| Operating Revenue | $2,797,000 | $38,913,000 | $26,004,000 | $110,777,000 |
| Expenses | ||||
| Total Expenses | $89,502,000 | $75,231,000 | $111,710,000 | $96,239,000 |
| Other Income Expense | $-59,369,000 | $-48,205,000 | $-155,135,000 | $23,263,000 |
| Other Non Operating Income Expenses | $-2,010,000 | $606,000 | $691,000 | $330,000 |
| Net Non Operating Interest Income Expense | $6,579,000 | $7,386,000 | $2,131,000 | $-3,031,000 |
| Operating Expense | $89,502,000 | $75,231,000 | $111,710,000 | $96,239,000 |
| General And Administrative Expense | $31,468,000 | $30,126,000 | $40,450,000 | $23,862,000 |
| Interest Expense | - | $0 | $2,833,000 | $3,031,000 |
| Interest Expense Non Operating | - | $0 | $2,833,000 | $3,031,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-130,302,000 | $-77,424,000 | $-219,710,000 | $35,379,000 |
| Net Interest Income | $6,579,000 | $7,386,000 | $2,131,000 | $-3,031,000 |
| Interest Income | $6,579,000 | $7,386,000 | $4,964,000 | - |
| Normalized Income | $-76,728,694 | $-38,863,310 | $-76,350,080 | $17,261,930 |
| Net Income From Continuing And Discontinued Operation | $-130,302,000 | $-77,424,000 | $-219,710,000 | $35,379,000 |
| Average Dilution Earnings | $0 | $-446,000 | $0 | - |
| Net Income Common Stockholders | $-130,302,000 | $-77,424,000 | $-257,260,000 | $35,379,000 |
| Net Income | $-130,302,000 | $-77,424,000 | $-219,710,000 | $35,379,000 |
| Net Income Including Noncontrolling Interests | $-130,302,000 | $-77,424,000 | $-219,710,000 | $35,379,000 |
| Net Income Continuous Operations | $-130,302,000 | $-77,424,000 | $-219,710,000 | $35,379,000 |
| Pretax Income | $-139,495,000 | $-77,137,000 | $-238,710,000 | $34,770,000 |
| Special Income Charges | $-61,054,000 | $-44,479,000 | $-19,010,000 | $0 |
| Interest Income Non Operating | $6,579,000 | $7,386,000 | $4,964,000 | - |
| Operating Income | $-86,705,000 | $-36,318,000 | $-85,706,000 | $14,538,000 |
| Total Operating Income As Reported | - | $-43,897,000 | $-86,416,000 | $14,538,000 |
| Per Share | ||||
| Diluted EPS | $-5.02 | $-4.49 | $-49.76 | $3.00 |
| Basic EPS | $-5.02 | $-4.48 | $-49.76 | $7.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,785,694 | $-10,250,310 | $-12,466,080 | $4,815,930 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-26,387,000 | $-27,175,000 | $-79,208,000 | $16,155,000 |
| Total Unusual Items | $-57,359,000 | $-48,811,000 | $-155,826,000 | $22,933,000 |
| Total Unusual Items Excluding Goodwill | $-57,359,000 | $-48,811,000 | $-155,826,000 | $22,933,000 |
| Reconciled Depreciation | $2,959,000 | $1,151,000 | $843,000 | $1,287,000 |
| EBITDA (Bullshit earnings) | $-83,746,000 | $-75,986,000 | $-235,034,000 | $39,088,000 |
| EBIT | $-86,705,000 | $-77,137,000 | $-235,877,000 | $37,801,000 |
| Diluted Average Shares | $25,973,329 | $17,357,943 | $5,170,319 | $4,862,496 |
| Basic Average Shares | $25,973,329 | $17,276,822 | $5,170,319 | $4,825,285 |
| Diluted NI Availto Com Stockholders | $-130,302,000 | $-77,870,000 | $-257,260,000 | $35,379,000 |
| Tax Provision | $-9,193,000 | $287,000 | $-19,000,000 | $-609,000 |
| Impairment Of Capital Assets | $56,700,000 | $7,579,000 | $710,000 | - |
| Restructuring And Mergern Acquisition | $4,354,000 | $36,900,000 | $18,300,000 | $0 |
| Gain On Sale Of Security | $3,695,000 | $-4,332,000 | $-136,816,000 | $22,933,000 |
| Research And Development | $58,034,000 | $45,105,000 | $71,260,000 | $72,377,000 |
| Selling General And Administration | $31,468,000 | $30,126,000 | $40,450,000 | $23,862,000 |
| Other Gand A | $31,468,000 | $30,126,000 | $40,450,000 | $23,862,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $37,550,000 | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-268,303,000 | $-205,565,000 | $-638,947,000 | $93,828,000 |
| Total Assets | $296,411,000 | $435,023,000 | $305,050,000 | $165,886,000 |
| Total Non Current Assets | $167,135,000 | $218,397,000 | $214,321,000 | $17,748,000 |
| Other Non Current Assets | $7,286,000 | $2,187,000 | $1,377,000 | $1,337,000 |
| Goodwill And Other Intangible Assets | $142,063,000 | $198,763,000 | $198,763,000 | $0 |
| Other Intangible Assets | $93,900,000 | $150,600,000 | $150,600,000 | - |
| Current Assets | $129,276,000 | $216,626,000 | $90,729,000 | $148,138,000 |
| Other Current Assets | $3,022,000 | $3,144,000 | $4,967,000 | $3,778,000 |
| Receivables | $1,115,000 | $872,000 | $8,851,000 | $9,758,000 |
| Accounts Receivable | $1,115,000 | $872,000 | $5,870,000 | $6,596,000 |
| Cash Cash Equivalents And Short Term Investments | $125,139,000 | $212,610,000 | $76,911,000 | $134,602,000 |
| Cash And Cash Equivalents | $125,139,000 | $212,610,000 | $76,911,000 | $106,438,000 |
| Other Receivables | - | - | $2,981,000 | $3,162,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $12,676,000 | $13,984,000 | $10,955,000 | $37,925,000 |
| Long Term Debt And Capital Lease Obligation | $8,525,000 | $11,133,000 | $8,789,000 | $27,841,000 |
| Current Debt And Capital Lease Obligation | $4,151,000 | $2,851,000 | $2,166,000 | $10,084,000 |
| Long Term Debt | - | - | - | $17,786,000 |
| Current Debt | - | - | - | $8,476,000 |
| Other Current Borrowings | - | - | - | $8,476,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $422,651,000 | $441,825,000 | $745,234,000 | $72,058,000 |
| Total Non Current Liabilities Net Minority Interest | $407,714,000 | $418,849,000 | $677,025,000 | $46,981,000 |
| Other Non Current Liabilities | $392,100,000 | $387,739,000 | $342,617,000 | - |
| Derivative Product Liabilities | $141,000 | $3,836,000 | $5,674,000 | $19,140,000 |
| Non Current Deferred Liabilities | $6,948,000 | $16,141,000 | $19,391,000 | $0 |
| Non Current Deferred Taxes Liabilities | $6,948,000 | $16,141,000 | - | - |
| Current Liabilities | $14,937,000 | $22,976,000 | $68,209,000 | $25,077,000 |
| Payables And Accrued Expenses | $10,786,000 | $12,364,000 | $17,883,000 | $14,400,000 |
| Payables | $1,288,000 | $288,000 | $3,150,000 | $316,000 |
| Accounts Payable | $1,288,000 | $288,000 | $3,150,000 | $316,000 |
| Other Current Liabilities | - | $7,761,000 | $45,849,000 | - |
| Current Deferred Liabilities | - | $0 | $2,311,000 | $593,000 |
| Interest Payable | - | - | $0 | $222,000 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-126,240,000 | $-6,802,000 | $-440,184,000 | $93,828,000 |
| Total Equity Gross Minority Interest | $-126,240,000 | $-6,802,000 | $-440,184,000 | $93,828,000 |
| Stockholders Equity | $-126,240,000 | $-6,802,000 | $-440,184,000 | $93,828,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,576,000 | $-4,621,000 | $-4,600,000 | $-4,558,000 |
| Other Equity Adjustments | $-4,576,000 | $-4,621,000 | $-4,600,000 | $-4,558,000 |
| Retained Earnings | $-822,373,000 | $-692,071,000 | $-614,647,000 | $-394,937,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $300,554,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $26,011,106 | $25,767,369 | $5,397,594 | $5,101,414 |
| Share Issued | $26,011,106 | $25,767,369 | $5,397,594 | $5,101,414 |
| Tangible Book Value | $-268,303,000 | $-205,565,000 | $-638,947,000 | $93,828,000 |
| Invested Capital | $-126,240,000 | $-6,802,000 | $-440,184,000 | $120,090,000 |
| Working Capital | $114,339,000 | $193,650,000 | $22,520,000 | $123,061,000 |
| Capital Lease Obligations | $12,676,000 | $13,984,000 | $10,955,000 | $11,663,000 |
| Total Capitalization | $-126,240,000 | $-6,802,000 | $-440,184,000 | $111,614,000 |
| Additional Paid In Capital | $700,706,000 | $689,887,000 | $179,062,000 | $493,308,000 |
| Capital Stock | $3,000 | $3,000 | $1,000 | $15,000 |
| Common Stock | $3,000 | $3,000 | $1,000 | $15,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $8,525,000 | $11,133,000 | $8,789,000 | $10,055,000 |
| Current Capital Lease Obligation | $4,151,000 | $2,851,000 | $2,166,000 | $1,608,000 |
| Current Accrued Expenses | $9,498,000 | $12,076,000 | $14,733,000 | $14,084,000 |
| Investments And Advances | $0 | $2,000,000 | $2,000,000 | $2,000,000 |
| Goodwill | $48,163,000 | $48,163,000 | $48,163,000 | $0 |
| Net PPE | $17,786,000 | $15,447,000 | $12,181,000 | $14,411,000 |
| Accumulated Depreciation | $-4,733,000 | $-2,357,000 | $-5,728,000 | $-5,205,000 |
| Gross PPE | $22,519,000 | $17,804,000 | $17,909,000 | $19,616,000 |
| Leases | $4,177,000 | $3,427,000 | $61,000 | $57,000 |
| Construction In Progress | $3,466,000 | $695,000 | $150,000 | $599,000 |
| Other Properties | $14,020,000 | $12,830,000 | $16,348,000 | $17,618,000 |
| Machinery Furniture Equipment | $856,000 | $852,000 | $1,350,000 | $1,342,000 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | - | $0 | $3,538,000 | $0 |
| Current Deferred Revenue | - | $0 | $2,311,000 | $593,000 |
| Other Short Term Investments | - | - | $0 | $28,164,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-79,395,000 | $-32,767,000 | $-51,367,000 | $-32,832,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-73,941,000 | $-23,674,000 | $-51,161,000 | $-31,631,000 |
| Cash Flow From Continuing Operating Activities | $-73,941,000 | $-23,674,000 | $-51,161,000 | $-31,631,000 |
| Operating Gains Losses | $-3,695,000 | $4,605,000 | $138,071,000 | $-21,029,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,454,000 | $-9,093,000 | $-206,000 | $-1,201,000 |
| Investing Cash Flow | $-5,454,000 | $-8,742,000 | $34,609,000 | $-15,002,000 |
| Cash Flow From Continuing Investing Activities | $-5,454,000 | $-8,742,000 | $34,609,000 | $-15,002,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $164,438,000 | $20,250,000 | $38,980,000 |
| Financing Cash Flow | $-8,055,000 | $168,428,000 | $-13,145,000 | $39,215,000 |
| Cash Flow From Continuing Financing Activities | $-8,055,000 | $168,428,000 | $-13,145,000 | $39,215,000 |
| Net Other Financing Charges | $-8,378,000 | $-66,000 | - | $-110,000 |
| Net Preferred Stock Issuance | $0 | $40,000,000 | $20,250,000 | $0 |
| Preferred Stock Issuance | $0 | $40,000,000 | $20,250,000 | $0 |
| Net Common Stock Issuance | $0 | $124,438,000 | $-6,169,000 | $38,980,000 |
| Common Stock Issuance | $0 | $124,438,000 | $0 | $38,980,000 |
| Repurchase Of Capital Stock | - | $0 | $-6,169,000 | $0 |
| Other | ||||
| End Cash Position | $126,874,000 | $214,279,000 | $78,288,000 | $108,038,000 |
| Beginning Cash Position | $214,279,000 | $78,288,000 | $108,038,000 | $115,436,000 |
| Effect Of Exchange Rate Changes | $45,000 | $-21,000 | $-53,000 | $20,000 |
| Changes In Cash | $-87,450,000 | $136,012,000 | $-29,697,000 | $-7,418,000 |
| Proceeds From Stock Option Exercised | $323,000 | $4,056,000 | $231,000 | $345,000 |
| Net PPE Purchase And Sale | $-5,454,000 | $-8,742,000 | $-206,000 | $-1,201,000 |
| Sale Of PPE | $0 | $351,000 | $0 | $0 |
| Purchase Of PPE | $-5,454,000 | $-9,093,000 | $-206,000 | $-1,201,000 |
| Change In Working Capital | $-8,063,000 | $-5,791,000 | $4,971,000 | $-60,377,000 |
| Change In Payables And Accrued Expense | $-2,522,000 | $-9,668,000 | $73,000 | $1,703,000 |
| Change In Accrued Expense | $-3,588,000 | $-6,741,000 | $-2,761,000 | $2,212,000 |
| Change In Payable | $1,066,000 | $-2,927,000 | $2,834,000 | $-509,000 |
| Change In Account Payable | $1,066,000 | $-2,927,000 | $2,834,000 | $92,000 |
| Change In Prepaid Assets | $-5,298,000 | $1,747,000 | $-1,265,000 | $2,471,000 |
| Change In Receivables | $-243,000 | $7,979,000 | $907,000 | $156,000 |
| Changes In Account Receivables | $-243,000 | $4,998,000 | $726,000 | $3,318,000 |
| Other Non Cash Items | $5,132,000 | $39,337,000 | $20,509,000 | $2,290,000 |
| Stock Based Compensation | $10,521,000 | $6,582,000 | $22,524,000 | $11,194,000 |
| Asset Impairment Charge | $58,700,000 | $7,579,000 | $710,000 | $0 |
| Deferred Tax | $-9,193,000 | $287,000 | $-19,000,000 | $0 |
| Deferred Income Tax | $-9,193,000 | $287,000 | $-19,000,000 | $0 |
| Depreciation Amortization Depletion | $2,959,000 | $1,151,000 | $843,000 | $1,287,000 |
| Depreciation And Amortization | $2,959,000 | $1,151,000 | $843,000 | $1,287,000 |
| Gain Loss On Investment Securities | $-3,695,000 | $4,332,000 | $136,854,000 | $-20,882,000 |
| Gain Loss On Sale Of PPE | $0 | $273,000 | $477,000 | $-147,000 |
| Net Income From Continuing Operations | $-130,302,000 | $-77,424,000 | $-219,710,000 | $35,379,000 |
| Repayment Of Debt | - | $0 | $-27,457,000 | $0 |
| Interest Paid Supplemental Data | - | $0 | $1,853,000 | $2,248,000 |
| Common Stock Payments | - | $0 | $-6,169,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $-27,457,000 | $0 |
| Net Long Term Debt Issuance | - | $0 | $-27,457,000 | $0 |
| Long Term Debt Payments | - | $0 | $-27,457,000 | $0 |
| Net Investment Purchase And Sale | - | $0 | $28,254,000 | $-13,801,000 |
| Sale Of Investment | - | $0 | $28,254,000 | $19,700,000 |
| Net Business Purchase And Sale | - | $0 | $6,561,000 | $0 |
| Sale Of Business | - | $0 | $6,561,000 | $0 |
| Change In Other Working Capital | - | $-5,849,000 | $5,256,000 | $-64,707,000 |
| Amortization Of Securities | - | $0 | $-79,000 | $-375,000 |
| Purchase Of Investment | - | - | $0 | $-33,501,000 |
| Change In Tax Payable | - | - | $0 | $-601,000 |
| Change In Income Tax Payable | - | - | $0 | $-601,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-15